Comparative Pharmacology
Head-to-head clinical analysis: THALIDOMIDE versus THALOMID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THALIDOMIDE versus THALOMID.
THALIDOMIDE vs THALOMID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Immunomodulatory and antiangiogenic action: TNF-alpha inhibitor, alters adhesion molecule expression, inhibits angiogenesis via VEGF/FGF inhibition, modulates T-cell co-stimulation and NF-κB activity.
Thalidomide is an immunomodulatory agent with antiangiogenic and anti-inflammatory properties. Its exact mechanism is not fully understood, but it inhibits tumor necrosis factor-alpha (TNF-α) production, modulates cytokine activity, and suppresses angiogenesis by inhibiting basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF).
100 mg orally once daily, preferably at bedtime to minimize sedation; maximum dose 400 mg daily for multiple myeloma or erythema nodosum leprosum.
200 mg orally once daily, taken with water preferably at bedtime to reduce sedation; dose may be titrated up to 400 mg daily based on tolerability.
None Documented
None Documented
Clinical Note
moderateThalidomide + Digoxin
"Thalidomide may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateThalidomide + Digitoxin
"Thalidomide may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateThalidomide + Deslanoside
"Thalidomide may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateThalidomide + Acetyldigitoxin
"Thalidomide may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 5-7 hours in healthy adults, but may be prolonged to 7-10 hours in patients with renal impairment or advanced age.
Mean terminal elimination half-life is approximately 5-7 hours in healthy adults; may be prolonged to 12-18 hours in patients with hepatic impairment due to decreased metabolism.
Thalidomide is primarily eliminated by nonenzymatic hydrolysis in plasma and tissues; renal excretion accounts for <1% of unchanged drug; metabolites are excreted renally (~90%) and fecally (~10%).
Primarily renal: >80% of absorbed dose excreted unchanged in urine. Minor fecal elimination (<15%). No significant biliary excretion.
Category D/X
Category C
Immunomodulatory Agent
Immunomodulatory Agent